Format

Send to

Choose Destination
See comment in PubMed Commons below
BMJ Case Rep. 2014 Jun 10;2014. pii: bcr2013202191. doi: 10.1136/bcr-2013-202191.

Persistence of hepatitis B surface antigen in blood in a chronic haemodialysis patient following vaccination booster.

Author information

1
Department of Virology, Royal Free London NHS Foundation Trust, London, UK.
2
Department of Renal Medicine, Royal Free London NHS Foundation Trust, London, UK.

Abstract

Patients receiving haemodialysis are at an increased risk of hepatitis B infection; regular screening for incident infection and vaccination of susceptible individuals is recommended. Haemodialysis patients often require repeated high-dose hepatitis B vaccination boosters because of impaired response. Since the hepatitis B surface antigen is used as an immunogenic agent for vaccination and as a marker of hepatitis B infection, it has occasionally been detected in the blood shortly after vaccine administration and can be mistaken for a new infection. These transient results, however, are unlikely to persist for longer than 14 days after vaccination. We report the case of a haemodialysis patient who tested weakly positive for hepatitis B surface antigen 52 days after a vaccine booster. This is the longest vaccine-induced antigenaemia described in the literature and indicates that vaccination can cause weakly positive hepatitis B surface antigen results for longer than previously reported.

PMID:
24916976
PMCID:
PMC4054484
DOI:
10.1136/bcr-2013-202191
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center